Ebselen
Ebselen is a small molecule pharmaceutical. It is currently being investigated in clinical studies. It is known to target ORF1a polyprotein;ORF1ab polyprotein.
Download report
Favorite
Commercial
Therapeutic Areas
No data
Trade Name
FDA
EMA
No data
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
No data
Labels
FDA
EMA
No data
Indications
FDA
EMA
No data
Agency Specific
FDA
EMA
No data
Patent Expiration
No data
ATC Codes
No data
HCPCS
No data
Clinical
Clinical Trials
13 clinical trials
View more details
Mock data
Subscribe for the real data
Subscribe for the real data
Indications Phases 4
No data
Indications Phases 3
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Meniere disease | D008575 | EFO_0006862 | H81.0 | 1 | 2 | 1 | — | — | 3 |
| Type 2 diabetes mellitus | D003924 | EFO_0001360 | E11 | — | 1 | 1 | — | — | 1 |
| Type 1 diabetes mellitus | D003922 | EFO_0001359 | E10 | — | 1 | 1 | — | — | 1 |
Indications Phases 2
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Ototoxicity | D000081015 | — | 2 | — | — | — | 2 | ||
| Covid-19 | D000086382 | U07.1 | — | 2 | — | — | — | 2 | |
| Coronavirus infections | D018352 | EFO_0007224 | B34.2 | — | 2 | — | — | — | 2 |
| Coronavirus | D017934 | — | 2 | — | — | — | 2 | ||
| Hearing loss | D034381 | EFO_0004238 | H91.9 | 1 | 1 | — | — | — | 2 |
| Bipolar disorder | D001714 | EFO_0000289 | F30.9 | — | 1 | — | — | — | 1 |
| Noise-induced hearing loss | D006317 | EFO_1001254 | — | 1 | — | — | — | 1 | |
| Head and neck neoplasms | D006258 | — | 1 | — | — | — | 1 | ||
| Lung neoplasms | D008175 | C34.90 | — | 1 | — | — | — | 1 | |
| Tinnitus | D014012 | HP_0000360 | H93.1 | — | 1 | — | — | — | 1 |
Show 1 more
Indications Without Phase
No data
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
| Drug common name | EBSELEN |
| INN | ebselen |
| Description | Ebselen is a benzoselenazole that is 1,2-benzoselenazol-3-one carrying an additional phenyl substituent at position 2. Acts as a mimic of glutathione peroxidase. It has a role as a neuroprotective agent, an apoptosis inducer, an anti-inflammatory drug, an antioxidant, a hepatoprotective agent, a genotoxin, a radical scavenger, an enzyme mimic, an EC 1.3.1.8 [acyl-CoA dehydrogenase (NADP(+))] inhibitor, an EC 1.8.1.12 (trypanothione-disulfide reductase) inhibitor, an EC 1.13.11.33 (arachidonate 15-lipoxygenase) inhibitor, an EC 1.13.11.34 (arachidonate 5-lipoxygenase) inhibitor, an EC 2.5.1.7 (UDP-N-acetylglucosamine 1-carboxyvinyltransferase) inhibitor, an EC 2.7.10.1 (receptor protein-tyrosine kinase) inhibitor, an EC 3.5.4.1 (cytosine deaminase) inhibitor, an EC 5.1.3.2 (UDP-glucose 4-epimerase) inhibitor, a ferroptosis inhibitor, an antifungal agent, an EC 3.4.22.69 (SARS coronavirus main proteinase) inhibitor, an anticoronaviral agent, an antibacterial agent, an antineoplastic agent and an EC 3.1.3.25 (inositol-phosphate phosphatase) inhibitor. |
| Classification | Small molecule |
| Drug class | — |
| Image (chem structure or protein) | |
| Structure (InChI/SMILES or Protein Sequence) | O=c1c2ccccc2[se]n1-c1ccccc1 |
Identifiers
| PDB | — |
| CAS-ID | 60940-34-3 |
| RxCUI | — |
| ChEMBL ID | CHEMBL51085 |
| ChEBI ID | 77543 |
| PubChem CID | 3194 |
| DrugBank | DB12610 |
| UNII ID | 40X2P7DPGH (ChemIDplus, GSRS) |
Target
Variants
Clinical Variant
No data
Financial
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Subscribe for the real data
Additional graphs summarizing 3,885 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
0 adverse events reported
View more details
Premium feature
Learn more about premium features at pharmakb.com
Learn more